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Summary
Background Elevated blood pressure incurs a major health and economic burden, particularly in low-income and 
middle-income countries. The Triple Pill versus Usual Care Management for Patients with Mild-to-Moderate 
Hypertension (TRIUMPH) trial showed a greater reduction in blood pressure in patients using fixed-combination, 
low-dose, triple-pill antihypertensive therapy (consisting of amlodipine, telmisartan, and chlorthalidone) than in 
those receiving usual care in Sri Lanka. We aimed to assess the cost-effectiveness of the triple-pill strategy.
Methods We did a within-trial (6-month) and modelled (10-year) economic evaluation of the TRIUMPH trial, using 
the health system perspective. Health-care costs, reported in 2017 US dollars, were determined from trial records and 
published literature. A discrete-time simulation model was developed, extrapolating trial findings of reduced systolic 
blood pressure to 10-year health-care costs, cardiovascular disease events, and mortality. The primary outcomes were 
the proportion of people reaching blood pressure targets (at 6 months from baseline) and disability-adjusted life-
years (DALYs) averted (at 10 years from baseline). Incremental cost-effectiveness ratios were calculated to estimate 
the cost per additional participant achieving target blood pressure at 6 months and cost per DALY averted over 
10 years.
Findings The triple-pill strategy, compared with usual care, cost an additional US$9·63 (95% CI 5·29 to 13·97) per 
person in the within-trial analysis and $347·75 (285·55 to 412·54) per person in the modelled analysis. Incremental 
cost-effectiveness ratios were estimated at $7·93 (95% CI 6·59 to 11·84) per participant reaching blood pressure 
targets at 6 months and $2842·79 (–28·67 to 5714·24) per DALY averted over a 10-year period.
Interpretation Compared with usual care, the triple-pill strategy is cost-effective for patients with mild-to-moderate 
hypertension. Scaled up investment in the triple pill for hypertension management in Sri Lanka should be supported 
to address the high population burden of cardiovascular disease.
Funding Australian National Health and Medical Research Council.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 
4.0 license.
Introduction
Elevated blood pressure is the leading risk factor for 
cardiovascular disease and is a major contributor to 
mortality worldwide,1 with the majority of the burden faced 
by low-income and middle-income countries.2 Achieving 
appropriate blood pressure control is challenging for 
people in low-income and middle-income countries 
because of therapeutic inertia, which might arise because 
the treating physician has assumed that the patient’s blood 
pressure has decreased sufficiently or guessed that existing 
treatment has yet to reach its full effect.3 Treatment gaps in 
such settings have contributed to the consequent high 
costs of hypertension-related hospital care.4
Initial or early use of fixed, low-dose, combination 
therapy for blood pressure reduction is seen as a 
promising strategy for reducing the burden of 
cardiovascular disease because of its proven efficacy5–7 and 
safety,8 as well as its potential ability to reduce therapeutic 
inertia9 and improve adherence to medication.10 Several 
clinical guidelines currently recommend use of dual 
combination therapy for initiation of treatment; however, 
currently, triple therapy is only recommended for 
individuals with severe hyper tension not controlled by 
dual therapy.11
Insufficient health economic evidence exists on whether 
a triple-pill therapy strategy is cost-effective compared 
with current incremental approaches to blood pressure 
lowering. A modelling study done in Greece12 found 
standard-dose, fixed-combination, triple-pill therapy to be 
cost-effective compared with its paired components 
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among people with moderate-to-severe hypertension. No 
evi dence currently exists comparing a low-dose, fixed-
combination triple pill with usual care as a first-line agent 
for patients with mild-to-moderate hypertension.
The Triple Pill versus Usual Care Management 
for Patients with Mild-To-Moderate Hypertension 
(TRIUMPH) trial9 found that more patients achieved 
their blood pressure target (relative risk 1·23 [95% CI 
1·09 to 1·39]) and that blood pressure reduction was 
greater (mean difference in systolic blood pressure [SBP] 
–9·8 mm Hg [95% CI –7·9 to –11·6]) with initial or early 
use of a low-dose, fixed-combination, triple-pill anti-
hypertensive therapy than with usual care in Sri Lanka 
over a 6-month period. We aimed to provide an economic 
evaluation of the TRIUMPH trial.
Methods
Study design and input population
We did a within-trial (6-month) and modelled (10-year) 
economic evaluation of the TRIUMPH trial from the 
health system perspective, comparing the use of a triple-
pill strategy with usual care in the treatment of people 
with mild-to-moderate hypertension. The TRIUMPH trial 
has been described in detail previously.9,13,14 In brief, 
TRIUMPH was a prospective, open-label, randomised 
controlled trial done in 11 urban hospital outpatient 
departments in Sri Lanka from Feb 15, 2016, to May 3, 2017. 
Patients were recruited to the trial if they were aged 
18 years and older, had persistent mild-to-moderate 
hypertension (SBP >140 mm Hg or diastolic blood 
pressure (DBP) >90 mm Hg; or SBP >130 mm Hg or DBP 
>80 mm Hg in patients with diabetes or chronic kidney 
disease), and were currently on no therapy or monotherapy 
only. Patients were randomly assigned to receive either the 
triple-pill therapy or usual care, stratified by study centre 
and use of blood pressure lowering therapy at baseline.
At baseline, the intervention group received the triple pill 
(with discontinuation of current monotherapy, if applicable) 
as part of their usual hypertension clinic visits. There were 
scheduled clinic visits at 6, 12, and 24 weeks (end of study), 
which included blood pressure measurement, potential 
changes in medications in line with local guidelines at the 
discretion of the treating physician, and assessment of 
adverse events. The triple pill consisted of two versions: 
lower dose (amlodipine 2·5 mg, telmisartan 20 mg, and 
chlorthalidone 12·5 mg) and higher dose (amlodipine 
5 mg, telmisartan 40 mg, and chlorthalidone 25 mg). The 
lower-dose version was administered to all participants 
initially, without any washout period for patients previously 
taking monotherapy. The higher-dose version and any 
other blood pressure lowering therapy could be used 
during follow-up, at the discretion of the treating physician. 
Further details about the manufacturing, capsulation, and 
quality of the triple pills used in the study have been 
described previously.9
The control group received usual care. At baseline, 
participants were administered blood pressure lowering 
medications as deemed appropriate by the treating 
physician and had scheduled follow-up clinic visits as per 
the intervention group. Ethics approval was provided by 
the Ethics Review Committee, Faculty of Medicine, 
University of Kelaniya (Kelaniya, Sri Lanka), and Royal 
Prince Alfred Hospital Ethics Review Committee 
(Sydney, NSW, Australia). The trial was registered with 
the Australian New Zealand Clinical Trials Registry 
(ACTRN12612001120864).
Research in context
Evidence before this study
We searched PubMed and Embase for economic evaluations of 
fixed, low-dose, triple-combination antihypertensive therapy 
published between database inception and Feb 20, 2019, using 
the search terms (“economic evaluation” OR “cost-effectiveness”) 
AND (“antihypertensive therapy” OR “triple pill” OR “triple 
combination”) AND “hypertension”. Only one study was 
identified in which a standard strength, fixed-combination, 
triple-pill antihypertensive therapy was cost-effective for the 
treatment of patients with moderate-to-severe hypertension, 
compared with its paired components in a high-income 
country. Currently, no evidence exists on the cost-effectiveness 
of a fixed, low-dose, triple-pill combination antihypertensive 
therapy for patients with mild-to-moderate hypertension.
Added value of this study
We did a within-trial and modelled economic evaluation of a 
fixed-combination, low-dose, triple-pill strategy compared with 
usual care for individuals with mild-to-moderate hypertension in 
Sri Lanka, based on findings from the Triple Pill versus Usual Care 
Management for Patients with Mild-To-Moderate Hypertension 
(TRIUMPH) trial. Our modelled economic evaluation results 
suggest that this triple-pill strategy is cost-effective as a first-line 
treatment option for individuals with mild-to-moderate 
hypertension, especially older individuals and those with higher 
blood pressure, through reductions in morbidity and mortality 
resulting from cardiovascular disease. The modelled results are 
highly sensitive to variations in the price of the triple pill.
Implications of all the available evidence
Our findings suggest that the use of low-dose, 
fixed-combination, triple-pill antihypertensive therapy in 
individuals with mild-to-moderate hypertension is 
cost-effective in a middle-income country setting. Compared 
with monotherapy, triple-pill therapy has the potential to lower 
blood pressure and reduce cardiovascular disease burden in 
Sri Lanka. This evidence should be used alongside 
considerations around implementation, feasibility, and budget 
impact for policy makers when making decisions around 
health-care resource allocation.
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Costs
During the trial, health system costs associated with 
clinic visits, medications, and inpatient hospital 
admissions were included in the analysis. Prescribed 
medications were recorded at each clinic visit. Follow-up 
clinic visits were costed using WHO’s Sri Lankan health-
centre cost estimates.15 At each follow-up period, 
participants from both groups completed questionnaires 
regarding outpatient clinic visits and inpatient hospital 
admission costs.
Pharmaceutical prices were obtained from the drug 
formulary of public hospitals in Sri Lanka, representing 
the amount paid by the government for each medicine.16 
All drugs were supplied and dispensed through the public 
health system in this study and thus the cost to the 
government represents the full cost. For the triple pill, we 
applied a cost of US$0·16 per day (irrespective of dose 
version), based on the price of a similar triple pill for 
hypertension in India. Further details on individual drug 
and triple-pill pricing are provided in the appendix (p 1).
The modelled economic evaluation focused on health 
system costs associated with clinic visits, cardiovascular 
disease-related hospital admissions, and antihypertensive 
medications. Prescribed antihypertensive medication 
costs were adopted from trial records (see appendix p 1 for 
further details), and costs associated with outpatient clinic 
visits, cardiovascular disease-related hospital admissions, 
and chronic cardiovascular disease were taken from the 
literature.15,17 All costs (when relevant) were inflated and 
presented in 2017 US dollars.
Cardiovascular disease model
A health economic model was developed to extrapolate 
trial-based findings of reduced blood pressure to long-term 
health-care costs and cardiovascular disease-related events 
and mortality. Similar to previous modelling methodology, 
we assumed that the medication recom mendations at 
baseline were held constant over a 10-year period.12
The aim of this discrete-time simulation model 
(figure 1) was to predict the occurrence of a first 
cardiovascular disease event or death. A cardiovascular 
disease event is defined as either myocardial infarction 
or stroke, with the model only potentially capturing 
one cardio vascular disease event per individual over a 
10-year period. In the model, all individuals started with 
no cardio vascular disease and at each annual cycle 
could experience a cardiovascular disease event and 
die, experience a cardio vascular event and survive, or 
die from cardio vascular disease-related or non-cardio-
vascular disease-related causes.
Fatal and non-fatal cardiovascular disease risk prediction
Data required to inform the model structure and 
parameters were based on a combination of trial-based 
data and findings from published academic literature 
(appendix pp 2–3, 7). 10-year fatal and non-fatal 
cardiovascular disease risks for the trial population were 
modelled using cardiovascular disease risk prediction 
equations known as Globorisk.18,19 In brief, the Cox 
proportional hazards regressions developed were based on 
more than 50 000 individuals in eight large prospective 
cohort studies, using age as the timescale. Globorisk was 
recalibrated using Sri Lankan population-specific mean 
risk factors (age, sex, smoking status, diabetes, total 
cholesterol, and SBP); however, the recalibrated model is 
limited to prediction for individuals aged 40–84 years at 
baseline because of questionable reliability of data in those 
aged 85 years and older.
Annual fatal and non-fatal cardiovascular disease risks 
were estimated using the recalibrated Sri Lankan 
Globorisk equations for each individual trial participant 
(see appendix pp 3–4 for further details). Baseline values 
for all individual risk factors were used except for age and 
SBP. Age was updated at each annual cycle and the end of 
study SBP measurement was used. Non-cardiovascular 
disease-specific mortality was calculated using 5-year age-
specific and sex-specific Sri Lankan life tables20 to account 
for competing risk of mortality. Cardiovascular disease 
(fatal and non-fatal) risk, cardiovascular disease-specific 
mortality, and non-cardiovascular disease-specific mor-
tality were converted into annual probabilities and applied 
to each individual.
We assumed a relative risk reduction in cardiovascular 
disease events (0·80 [95% CI 0·77–0·83]) and all-cause 
mortality (0·87 [0·84–0·91]) for every 10 mm Hg 
reduction in SBP, on the basis of a recent systematic 
review and meta-analysis of randomised controlled 
trials.21 We assumed no changes to adherence or non-
adherence of antihypertensive medication from the end 
of study measurements in TRIUMPH in our model. 
Given the lack of long-term evidence on whether changes 
in SBP are sustained by the triple pill, we assumed 
reductions in SBP achieved in the trial to diminish by 
30% in the second year for both groups, with no further 
change in SBP in the following years.
Outcomes
For the within-trial economic evaluation, the primary 
outcome was the proportion of participants achieving 
target blood pressure (SBP <130 mm Hg and DBP 
Figure 1: Structure of the discrete-time simulation model, depicting different health states that individuals 
could be in at each annual cycle
No cardiovascular 
disease event 
Cardiovascular disease event Cardiovascular disease-related
death
Non-cardiovascular 
disease-related death
Chronic cardiovascular disease
See Online for appendix
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<80 mm Hg for patients with diabetes or chronic kidney 
disease or SBP <140 mm Hg and DBP <90 mm Hg 
otherwise) from baseline to 6 months.
In the modelled economic evaluation, the primary 
outcome was disability-adjusted life-years (DALYs) 
averted over a 10-year period. DALYs were quantified 
using WHO and Global Burden of Disease Study 
methodology.22 Disability weights for cardiovascular 
disease were adopted from the literature,23 using a mean 
weight attributed to myocardial infarction and moderate-
to-severe stroke, resulting in a DALY weight of 0·39 for 
the year of, and each year subsequent to, the onset of 
cardiovascular disease (see appendix p 2 for more detail). 
Following death, a disability weight of 1 was used to value 
each year of life lost up to 10 years from baseline.
Statistical analysis
Participants from the main trial were excluded from the 
within-trial analysis if health-care costs were missing 
or they withdrew consent from the study. Costs and 
effects were derived from patient-level data in the within-
trial analysis; we estimated a log binomial model for 
participants achieving target blood pressure at 6 months 
and a longitudinal model for costs, using hospital 
clinic as a random effect and the stratification factor 
(whether patients were on monotherapy or naive at 
baseline) as a fixed effect. Incremental cost-effectiveness 
ratios (ICERs) were calculated to estimate the cost per 
additional participant achieving target blood pressure.
Participants were excluded from the modelled 
economic evaluation if they were not aged between 
40 and 84 years at baseline, had a history of cardiovascular 
disease, did not have their SBP measured at a clinic, or 
died during the study. The model estimated ICERs per 
DALY averted over a 10-year period. A discount rate of 
3% was used.24
To account for uncertainty around the price estimates 
of the triple pill, we did one-way sensitivity analyses for 
both within-trial and modelled economic evaluations on 
two scenarios: triple-pill price of US$0·05 per day and 
$0·50 per day.
For the modelled economic evaluation, several other 
scenarios were considered to investigate uncertainty 
around model inputs and its impact on the ICER. 
We did separate sensitivity analyses with changes in 
specific parameters: cardiovascular disease-related hospital 
admission and clinic visit costs; relative risk estimates 
associated with SBP reduction and cardio vascular disease 
incidence and mortality; reductions in SBP achieved 
in the trial to drop by 60% in the following year; 
cardiovascular disease-specific DALY weights; and the 
discount rate. In addition, we did subgroup analyses: 
younger (40–59 years) and older (60 years and older) 
age groups, and lower (<155 mm Hg) and higher 
(≥155 mm Hg) SBP groups. Finally, we included a scenario 
that incorporated an age-related annual increase in SBP in 
both triple-pill and usual care groups.25
In addition to one-way sensitivity analyses, we 
did probabilistic sensitivity analyses using 1000 boot-
strap replications with replacement for both within-
trial and modelled analyses. For the modelled analyses, 
the bootstrapped cost and DALY pairs were plotted 
on an incremental cost-effectiveness plane. Using the 
bootstrapped estimates, a cost-effectiveness acceptability 
curve was derived to determine the probability that the 
intervention is below a range of willingness to pay 
thresholds.26 We used SAS Enterprise Guide, version 7.15, 
for the within-trial economic evaluation. We used 
Stata SE, version 14.2, for the modelled analysis.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
700 participants were enrolled into the trial, with 
349 randomly assigned to the triple-pill group and 
351 to the usual care group. After application of our 
exclusion criteria, there were 318 individuals in the 
triple-pill group and 329 individuals in the usual care 
group for the within-trial analysis. The modelled 
economic evaluation consisted of 261 individuals in the 
triple-pill group and 277 individuals in the usual care 
Within-trial analysis Modelled analysis
Triple-pill 
group (n=318)
Usual care 
group (n=329)
Triple-pill 
group (n=261)
Usual care 
group (n=277)
Age, years 56·2 (11·2) 56·0 (10·7) 57·0 (8·8) 57·2 (9·2)
Sex
Male 129 (41%) 143 (43%) 96 (37%) 120 (43%)
Female 189 (59%) 186 (57%) 165 (63%) 157 (57%)
Current cigarette or pipe smoker, or 
tobacco chewer
34 (11%) 32 (10%) 28 (11%) 25 (9%)
Body-mass index, kg/m² 26·0 (4·5) 26·3 (4·4) 25·9 (4·5) 26·2 (4·3)
Systolic blood pressure, mm Hg 154·1 (11·1) 154·2 (11·6) 154·6 (11·5) 154·9 (11·7)
Systolic blood pressure categories
<130 mm Hg 4 (1%) 2 (1%) 4 (2%) 2 (1%)
130–139 mm Hg 26 (8%) 31 (9%) 19 (7%) 24 (9%)
140–149 mm Hg 94 (30%) 99 (30%) 76 (29%) 81 (29%)
150–159 mm Hg 95 (30%) 89 (27%) 74 (28%) 74 (27%)
≥160 mm Hg 99 (31%) 108 (33%) 88 (34%) 96 (35%)
Total cholesterol, mg/dL 5·2 (1·2) 5·3 (1·2) 5·3 (1·3) 5·3 (1·2)
Using blood pressure lowering 
medications
126 (40%) 139 (42%) 102 (39%) 114 (41%)
Diabetes 96 (30%) 102 (31%) 75 (29%) 83 (30%)
Coronary artery disease 28 (9%) 21 (6%) ·· ··
Cerebrovascular disease 12 (4%) 7 (2%) ·· ··
Data are mean (SD) or n (%). Percentages might not sum to 100% as a result of rounding.
Table 1: Baseline characteristics 
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group. Table 1 presents the characteristics of the study 
participants.
The triple-pill strategy, compared with usual care, cost 
an additional US$9·63 (95% CI 5·29 to 13·97) per person 
in the within-trial analysis and $347·75 (285·55 to 
412·54) per person in the modelled analysis. Over a 
6-month period, the bootstrapped analysis indicated an 
ICER of $7·93 (95% CI 6·59 to 11·84; table 2) 
per participant reaching blood pressure targets. The 
modelled economic evaluation showed the triple pill to 
be cost-effective compared with usual care over a 10-year 
period. The base case analysis showed that the triple-pill 
group had a 10-year cardiovascular disease prevalence of 
15·15% (95% CI 8·43 to 21·46), compared with 19·73% 
(12·27 to 27·44) in the usual care group, which translates 
to 0·13 DALYs averted. The ICER was estimated at 
$2842·79 (95% CI –28·67 to 5714·24) per DALY averted.
In the sensitivity analysis, ICERs were robust to 
uncertainties around specific parameters, with some key 
exceptions (table 3; appendix p 8). Using a triple-pill price 
of US$0·05 per day and $0·50 per day resulted in the 
largest changes, with ICERs estimated at $0·82 and 
$29·90 per individual reaching blood pressure targets 
for the within-trial economic evaluation (appendix p 8) 
and $172 and $11 098 per DALY averted for the modelled 
economic evaluation (table 3), respectively. Changes in 
cardiovascular disease-related health-care costs and DALY 
weights, the effect size of SBP reduction on cardiovascular 
disease and all-cause mortality, increase in SBP in the year 
following the trial, an annual increase in SBP, and the 
Prevalence of 
cardiovascular disease 
(95% CI)
Mean total costs (US$) Mean DALYs ICER per DALY 
averted
Triple-pill 
group 
(n=261)
Usual care 
group 
(n=277)
Triple-pill 
group 
(n=261)
Usual care 
group 
(n=277)
Difference Triple-pill 
group 
(n=261)
Usual care 
group 
(n=277)
Difference
Base case 15·15% 19·73% $864 $516 $348 0·39 0·51 0·13 $2843
Triple-pill cost $0·05 per day 15·15% 19·73% $539 $516 $23 0·39 0·51 0·13 $172
Triple-pill cost $0·50 per day 15·15% 19·73% $1869 $516 $1353 0·39 0·51 0·13 $11 098
Hospital admission and clinic visit costs reduced by 25% 15·15% 19·73% $766 $406 $360 0·39 0·51 0·13 $2741
Hospital admission and clinic visit costs increased by 25% 15·15% 19·73% $962 $626 $335 0·39 0·51 0·13 $2976
Change in SBP effect on cardiovascular disease-specific 
and all-cause mortality reduced by 25%
17·01% 21·52% $80 $536 $344 0·43 0·55 0·12 $3839
0% discount rate 15·15% 19·73% $982 $588 $394 0·46 0·61 0·15 $3642
5% discount rate 15·15% 19·73% $798 $476 $322 0·34 0·46 0·11 $2427
DALY weight reduced by 25% 15·15% 19·73% $864 $516 $348 0·35 0·46 0·11 $2238
DALY weight increased by 25% 15·15% 19·73% $864 $516 $348 0·42 0·56 0·14 $2705
Age group 40–59 years 10·09% 13·75% $832 $473 $359 0·24 0·36 0·12 $4081
Age group 60 years and older 23·05% 28·22% $915 $575 $340 0·61 0·72 0·11 $2691
Baseline SBP <155 mm Hg 16·41% 17·41% $858 $557 $301 0·40 0·48 0·08 $3858
Baseline SBP ≥155 mm Hg 13·84% 22·17% $871 $482 $389 0·37 0·54 0·17 $1778
Reductions in SBP achieved within-trial to reduce by 
60% after first year
16·90% 21·10% $881 $532 $349 0·43 0·55 0·12 $5618
0·48 mm Hg increase in SBP per year 15·80% 20·54% $870 $525 $345 0·40 0·53 0·13 $2649
DALY=disability-adjusted life-year. ICER=incremental cost-effectiveness ratio. SBP=systolic blood pressure. 
Table 3: One-way sensitivity analysis of modelled costs, disability-adjusted life-years averted, cardiovascular disease prevalence, and incremental cost-effectiveness ratios over a 10-year 
period
Mean total costs (95% CI) Mean outcomes (95% CI) ICER per outcome 
(95% CI)
Triple-pill group Usual care group Mean difference Triple-pill group Usual care group Relative risk or 
mean difference 
(95% CI)
Blood pressure target achieved at 
6 months (within-trial analysis)
$29·56 
(26·31 to 32·81)
$19·93 
(16·78 to 23·07)
$9·63 
(5·29 to 13·97)
66·04% 
(60·59 to 71·98)
54·36% 
(49·16 to 60·11)
1·21 
(1·08 to 1·37)
$7·93 
(6·59 to 11·84)
DALYs averted over 10 years (modelled 
analysis)*
$863·90 
(821·08 to 905·88)
$516·15 
(469·70 to 563·81)
$347·75 
(285·55 to 412·54)
0·39 
(0·26 to 0·51)
0·51 
(0·38 to 0·65)
0·13 
(–0·07 to 0·31)
$2842·79 
(–28·67 to 5714·24)
DALYs=disability-adjusted life-years. ICER=incremental cost-effectiveness ratio. *Costs were discounted (3%) to 2017 US dollars.  
Table 2: Mean outcomes, mean costs (US$), and difference and incremental cost-effectiveness ratios per person by triple-pill and usual care groups, for 1000 bootstrapped replications
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discount rate resulted in small changes to the ICER, 
ranging from $2238 to $5618 per DALY averted (table 3).
The incremental cost-effectiveness plane (figure 2) and 
cost-effectiveness acceptability curve (figure 3) of the 
1000 bootstrapped estimates of the modelled base case 
analysis showed that 80% of bootstrapped ICERs were 
cost-effective at a hypothetical threshold of $6100 per 
DALY averted.
Discussion
To our knowledge, this is the first economic evaluation 
of a low-dose, fixed-combination, triple-pill strategy 
compared with usual care for treatment of people with 
mild-to-moderate hypertension. Our within-trial analysis 
showed ICERs of US$7·93 per participant reaching 
blood pressure targets and $2842·79 per DALY averted. 
The modelled ICER suggests that the triple-pill strategy 
is cost-effective, with a high proportion of bootstrapped 
replications being cost-effective at increasing willingness 
to pay thresholds.
The deterministic sensitivity analysis indicated that the 
findings were robust to variations in all key parameters 
except the price of the triple pill. Sri Lanka does not 
currently have any triple-pill antihypertensive combi-
nations on the market, and the price used for the base case 
analysis (US$0·16 per day) was based on an Indian triple 
pill. At this price, the triple pill is cost-effective. Given that 
the cost of the individual components of the triple pill are 
around $0·09 per day, this represents a 75% mark-up in 
price and is not an unreasonable assumption. The 
sensitivity analysis indicates that the triple pill remains 
cost-effective up to a cost of around US$0·50 per day.
The major strength of the study is that data used to 
inform the economic evaluations were from a randomised 
controlled trial and supplemented with additional 
Sri Lankan population-specific information when 
required. Findings from this study support the results of 
a study12 that showed that a standard-dose, fixed-
combination, triple pill  was cost-effective compared with 
its paired components, albeit in a high-income country, 
for indiv iduals with moderate-to-severe hypertension. 
Our subgroup analyses for individuals with higher SBP 
(table 3) corroborate these findings, reaffirming that 
triple-pill therapy is cost-effective for individuals with a 
high cardiovascular disease risk.
Our findings are important because they demonstrate 
the cost-effectiveness of an antihypertensive triple-
pill strategy relative to usual care for primary prevention 
in a population with mild-to-moderate hypertension. 
In limited-resource settings such as Sri Lanka, where 
there are large and increasing gaps in treatment 
for cardio vascular disease, the study provides a strong 
economic case for scaling up this intervention as a 
means of addressing the population burden of cardio-
vascular disease. Sri Lankan policy makers can use this 
evidence alongside context-specific considerations around 
feasibility, implementation, and budget impact when 
making funding decisions.
We believe our results are conservative because of 
several assumptions made in the analyses. A key 
argument for the triple-pill strategy versus usual care is 
that one would expect an improvement of adherence and 
persistence to treatment, which translates to improved 
SBP control and ultimately reductions in cardiovascular 
disease. Evidence exists for improved adherence to 
combination therapy containing multiple different drug 
classes compared with usual care in patients with cardio-
vascular disease.27 Additionally, large-scale adminis trative 
databases have shown improvements in adherence as 
well as clinical events specifically related to initiation of 
hypertension therapy with dual combinations.28 However, 
there is insufficient literature as yet suggesting a similar 
effect for the triple pill to treat hypertension. Thus, 
Figure 2: Incremental cost-effectiveness plane of 1000 bootstrap replications assessing the additional cost per 
disability-adjusted life-year (DALY) averted, comparing the use of the triple pill versus usual care
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Figure 3: Cost-effectiveness acceptability curve
The probability that the triple-pill strategy is cost-effective compared with usual 
care for individuals with mild-to-moderate hypertension at different willingness 
to pay thresholds for each disability-adjusted life-year (DALY) averted.
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we have conservatively assumed no changes in long-
term medication adherence, based on findings from 
TRIUMPH’s 6-month trial period.9 The model assumed 
individuals would incur up to one cardiovascular disease 
event over a 10-year period, an assumption that is 
not unreasonable given the relatively low risk in 
these individuals. Our results showed that the triple 
pill reduced the occurrence of a primary cardiovascular 
disease event, which would presumably lower the likeli-
hood of recurrent cardiovascular disease events and 
subsequently reduce health-care costs. We have assumed 
costs associated with the triple pill to be substantially 
more than the sum of the three individual components, 
reflecting the expensive entry price as a branded 
formulation. As generic formulations enter the market, 
the costs of the triple pill will decrease over time29 and 
subsequently become increasingly cost-effective, as can 
be seen in our sensitivity analyses.
There are some potential limitations to our study, which 
are due mainly to limitations of available data. We 
assumed the treatment effect of the trial to persist for 
10 years, with a 30% reduction in treatment effect 
after the first year and then no subsequent change in 
following years. Other medication costs that are associated 
with cardiovascular disease risk management, such as 
lipid lowering therapy or escalation of antihypertensive 
treatment, were not included in the analysis, although 
one would not expect these costs to differ between 
treatment groups. We were unable to distinguish between 
different cardiovascular disease event types because of 
paucity of Sri Lankan data. The complexities surrounding 
changes in risk factors associated with cardiovascular 
disease risk over time meant that we restricted our 
analysis to a 10-year horizon. Although the main trial 
found no significant differences in the occurrence of 
serious adverse events between the triple-pill and usual 
care groups over a 6-month period, further research is 
required to observe serious adverse events over a long-
term period. Finally, although we cannot rule out a 
potential Hawthorne effect within the TRIUMPH trial, 
we believe that it is unlikely to bias the reduction in SBP 
between groups. However, long-term effectiveness data 
from longitudinal large-scale administrative databases 
can be used to inform this future research question.
The TRIUMPH trial showed a strategy of initial or 
early use of a triple-pill combination to be effective 
compared with usual care in Sri Lanka and, in the 
long term, a highly cost-effective first-line strategy to 
lower cardiovascular disease risk in people with mild-to-
moderate hypertension. The solid economic case for 
scaling up this intervention to a population level can be 
further strengthened with economies of scale and future 
reductions in the price of such medicines.
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